Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura (Q24241470)

thrombotic thrombocytopenic purpura

Europe PubMed Central

title

Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura (English)

0 references

1 reference

1 reference

5

Jonathan C Craig

0 references

Elizabeth J. Elliott

2

object named as

Elizabeth J Elliott

0 references

author name string

Mini Michael

1

0 references

Greta F Ridley

3

0 references

Elisabeth M Hodson

Cochrane Database of Systematic Reviews

4

0 references

publication date

21 January 2009

0 references

published in

0 references

cites work

Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Steroids in the hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Heparin therapy in the hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Surveillance for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Treatment of Thrombotic Thrombocytopenic Purpura with Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Société de Néphrologie Pédiatrique

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Renal failure and renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Heterogeneity of atypical haemolytic uraemic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Hemolytic-uremic syndrome and complement factor H deficiency: clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Increasing mortality from thrombotic thrombocytopenic purpura in the United States--analysis of national mortality data, 1968-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

The hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003595.PUB2

Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP.

21 January 2018

1 reference

12 December 2020

Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura

1 reference

12 December 2020

Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases

1 reference

12 December 2020

Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial

1 reference

12 December 2020

Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura

1 reference

12 December 2020

Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials

1 reference

12 December 2020

Vincristine for thrombotic thrombocytopenic purpura

1 reference

12 December 2020

10.1002/14651858.CD003595.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19160220

1 reference

Consolidated OpenCitations Corpus – April 2017